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A B S T R A C T
There is no abstract. The objectives are as follows:
To evaluate the benefits and harms of antiplatelet therapy in patients with any form of kidney disease, including patients with CKD not
receiving renal replacement therapy (RRT), patients receiving any form of dialysis, and kidney transplant recipients.
P L A I N   L A N G U A G E   S U M M A R Y
[Plain language title]
 [Summary text]
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B A C K G R O U N D
Description of the condition
Cardiovascular disease is the leading cause of morbidity and
mortality in all stages of chronic kidney disease (CKD) (Casas 2005;
Keith 2004; Mann 2001; Norris 2006; Sarnak 2003; Weiner 2004a;
Weiner 2004b) including the CKD of renal transplant recipients
(US Renal Data system. 2008, Australia and New Zealand Dialysis
and Transplant registry (ANZDATA), (Aakhus 1999; Kasiske 2000;
Ojo 2000). Compared with the general population, the risk of
cardiovascular disease is increased two-fold in early CKD (Go 2004)
and 10 to 20-fold in dialysis patients (Fort 2005) in whom it accounts
for 50% of all deaths (Collins 2003). Population representative
surveys in Australia (AusDiab Survey 2003) and United States
(NHANES 2010) have shown a CKD prevalence of approximately
16% in the adult population. With the increasing prevalence of
some of the known risk factors for CKD including hypertension,
obesity and diabetes (Fields 2004; Koren-Morag 2006; Mokdad
2003), the burden of CKD and its complications are projected
to increase and to significantly contribute to global health care
expenditure.
How the intervention might work
Platelets play a pivotal role in thrombosis and various available
antiplatelet agents block platelet activation and aggregation at
various points in the thrombotic cascade. Currently available data
suggests that antiplatelet agents might be beneficial in patients
with CKD for primary (ATT 2002; Ruilope 2001) and secondary
(Berger 2003; McCullough 2002) prevention of cardiovascular
events. Antiplatelet agents might have beneficial eGects on the
kidney, possibly reducing proteinuria and protecting renal function
in patients with glomerulonephritis (Taji 2006; Zauner 1994),
and improving graP function in people with kidney transplants
(Bonomini 1986; Frasca 1986). However some have reported that
the eGicacy of antiplatelet therapy in CKD might be lower than for
other high cardiovascular risk populations (Best 2008). Despite this,
the Kidney Disease Outcomes Quality Initiative guideline program
(KDOQI) has supported the use of aspirin for primary prevention
of cardiovascular disease in CKD. Antiplatelet agents appear to
have a modest eGect on the preservation of arteriovenous fistula
patency (Dember 2008). Their use for fistula preservation and as
part of a multi-factorial intervention strategy for patients with CKD
is advocated by guideline groups (British Renal Association, Caring
for Australians with Renal Impairment (CARI) group and Canadian
Society of Nephrology).
Why it is important to do this review
To date, there has been no formal meta-analysis of the benefits
and harms of antiplatelet agents in patients with CKD. In contrast
to the general population, patients with CKD have a combination
of traditional and non traditional cardiovascular risk factors (Foley
1998; Foley 2003; Roberts 2006; Shah 2008). In addition, people
with CKD might have diGerent mechanisms for cardiovascular
disease, including arrhythmia and congestive heart failure (Amann
2003; Curtis 2005; Dikow 2005; Foley 1995; Remppis 2008), altered
pharmacokinetics (Mosenkis 2004; Scheen 2008) and impaired
haemostasis (Kaw 2006; Remuzzi 1988; Wattanakit 2008; Zwaginga
1991). Compared to patients without CKD, these factors might
expose them to a diGerent spectrum of risk and benefit from
antiplatelet therapy.
This systematic review aims to assess the relative benefits
and harms of any antiplatelet agents for the prevention of
cardiovascular disease and kidney disease progression in patients
with CKD.
O B J E C T I V E S
To evaluate the benefits and harms of antiplatelet therapy in
patients with any form of kidney disease, including patients
with CKD not receiving renal replacement therapy (RRT), patients
receiving any form of dialysis, and kidney transplant recipients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider for inclusion all RCTs of any antiplatelet agent
in patients with CKD where the duration of follow-up was two
months or longer. We define patients with CKD as those who are
receiving any form of RRT, have a functioning kidney transplant,
or have impaired kidney function defined as a reduced glomerular
filtration rate (GFR < 60 mL/min/1.73 m2), the presence of other
markers of kidney damage such as proteinuria (KDOQI stages 1-5),
an elevated serum creatinine (SCr > 120 mmol/L) or as defined
by study authors.  Data from CKD subgroups within studies with
broader inclusion criteria (e.g. people from the general population,
people with diabetes, people with cardiovascular disease), which
report outcomes for participants with CKD, will also be considered
for inclusion.
Types of participants
All adults (>18 years of age) with CKD as defined above. Separate
analyses will be undertaken for:
• Kidney transplant recipients• Individuals undergoing any form of maintenance dialysis
therapy• People with CKD stage 1-4 and CKD stage 5 who are not receiving
RRT, as defined by KDOQI guidelines or as defined by author
Types of interventions
We will include studies of any antiplatelet agent. Agents can
be administered at any dose or route of administration, and be
compared with placebo, no treatment, diGerent dose of the same
or diGerent antiplatelet agents, diGerent administration regimens
of the same or diGerent agent, or diGerent combinations of
antiplatelet agents. Antiplatelet agents will include (but not limited
to): acetylsalicylic acid (aspirin), adenosine reuptake inhibitors
(dipyridamole), adenosine diphosphate receptor inhibitors
(ticlopidine and clopidogrel), phosphodiesterase 3 inhibitors
(cilostazol), P2Y12 antagonists (prasugrel, ticagrelor, cangrelor,
elinogrel), glycoprotein IIB/IIIA inhibitors (abciximab, eptifibatide,
tirofiban, defibrotide), sulfinpyrazone, or preparations in which one
or more antiplatelet agents are combined with other drugs.
Studies in which participants receive co-interventions other than
antiplatelet agents will also be included.
We will exclude studies in which duration of follow-up was fewer
than two months.
Antiplatelet agents for chronic kidney disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Types of outcome measures• Cardiovascular events* Composite endpoints of major adverse cardiovascular events
(myocardial infarction, stroke)* Myocardial infarction (fatal or non-fatal)* Ischaemic stroke (fatal or non-fatal)• Death* All-cause mortality* Cardiovascular including sudden death* Bleeding related• Kidney outcomes* Incidence of end-stage kidney disease requiring RRT* Doubling of SCr or other threshold of renal dysfunction as
defined by authors* End of treatment SCr (mg/dL or mmol/L)* Change in SCr from beginning to end of treatment* End of treatment GFR (mL/min or mL/min/1.73 m2) assessed
by any measure or change from beginning to end of
treatment* New onset albuminuria (urinary albumin to creatinine ratio
(ACR): > 3.5 mg/mmol (women) or > 2.5 mg/mmol (men))* Regression of microalbuminuria to normoalbuminuria (<
3.5 mg/mmol (women) or < 2.5 mg/mmol (men)); or
macroalbuminuria (urinary ACR > 35 mg/mmol (women), > 25
mg/mmol (men)) to microalbuminuria or normoalbuminuria
or as defined by authors* Change in albuminuria from beginning to end of treatment* End of treatment albuminuria (mg/mmol or µg/min)* Change in albuminuria from beginning to end of treatment* End of treatment 24 hour urine protein excretion (g/24 h) or
change from beginning to end of treatment• Antiplatelet agents’ specific toxicity* Fatal bleeding events* Major bleeding events (defined as haemorrhage or
any bleeding episode that necessitates hospitalisation,
transfusion, or as defined by study authors)* Minor bleeding events* Any bleeding event (major or minor)* Gastro-intestinal disturbances (abdominal pain or peptic
ulcer disease, or as defined by the authors)• All-cause hospitalisation• Treatment crossover or withdrawal• Any other adverse event as reported by triallists• Interruption of treatment (treatment withdrawals) for any
reason
Search methods for identification of studies
Electronic searches
We will conduct electronic searches of the following databases:
1. The Cochrane Renal Group’s specialised register and the
Cochrane Central Register of Controlled Trials (CENTRAL) in the
Cochrane library (most recent) will be searched. These registers
contain the hand searched results of conference proceedings
from general and speciality meetings. This is an ongoing activity
across the Cochrane Collaboration and is both retrospective and
prospective. Therefore we will not specifically search conference
proceedings. Please refer to The Cochrane Renal Group's Module
in The Cochrane Library for the most up-to-date list of conference
proceedings (Renal Group 2010).
2. MEDLINE (from 1966) using the optimally sensitive strategy
developed by the Cochrane Collaboration for the identification
of RCTs (Lefebvre 2008) with a search strategy developed
with input from the Cochrane  Renal Group's  Trial Search Co-
ordinator.
3. EMBASE (from 1980) using the optimally sensitive strategy
developed by the Cochrane Collaboration for the identification
of RCTs (Lefebvre 2008) with a search strategy developed
with input from the Cochrane  Renal Group's Trial Search Co-
ordinator.
See Appendix 1 for search terms used.
Additionally, we will search the US registry of federally and privately
supported clinical studies at http://www.clinicaltrials.gov/ for
ongoing or unpublished RCTs that meet our inclusion criteria.
Searching other resources
Also handsearching will be performed, i.e. checking the reference
lists of retrieved studies and systematic reviews to identify other
relevant studies. Resulting references will be double-checked and
matched with the results of the systematic literature search.
Corresponding authors of all large studies with broader inclusion
will also be contacted to obtain data for the CKD population if
available.
Data collection and analysis
Selection of studies
All RCTs enrolling patients with CKD as defines above, including
patients on RRT and recipients of a kidney transplant will
be considered. RCT including participants without CKD will be
excluded unless specific subpopulation data for those with CKD are
available.
Based on the search strategy described, we will identify titles
and abstracts that may be relevant to this systematic review. Two
independent authors will then screen the titles and abstracts and
select the ones that meet the inclusion criteria. Discrepancies in
selection will be resolved by discussion or by the review of an
experienced arbitrator.
Studies reported in non-English language journals will be
translated before assessment and the process will be defined in the
review.
Data extraction and management
Two authors will independently read the full text of extracted
articles, assess their methodological quality and include studies
that meet the inclusion criteria. Where more than one publication
of one study exists, reports will be grouped together and only
the publication with the most complete data will be used in the
analyses. Where relevant outcomes are only published in earlier
versions this data will be used. Any discrepancy between published
versions will be highlighted.
Two independent authors will use standardised data forms to
extract data on:
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• Study design• Participants: patients baseline characteristics including age,
gender, race, diabetic status (% with diabetes and type of
diabetes), hypertension status (% with hypertension), smoking
status (% smokers), visceral obesity (% with visceral obesity as
defined by authors), previous cardiovascular events (% with)
and history of cardiovascular diseases (% with), stage of CKD• Interventions and comparisons: diGerent antiplatelet
agents and diGerent doses and route of administration used• Outcomes: all-cause mortality, cardiovascular events and
mortality, renal outcomes and toxicity
Assessment of risk of bias in included studies
The quality of included studies will be formally assessed by looking
at standard quality domains using the risk of bias assessment tool
(Higgins 2008).
• Was there adequate sequence generation?• Was allocation adequately concealed?• Was knowledge of the allocated interventions adequately
prevented during the study?• Were incomplete outcome data adequately addressed?• Are reports of the study free of suggestion of selective outcome
reporting?• Was the study apparently free of other problems that could put
it at a risk of bias?
We will make explicit judgements (Appendix 2) regarding whether
studies are at high risk of bias, according to the criteria given in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008). With reference to the six points as described above, we will
assess the likely magnitude and direction of the bias and whether
we consider it is likely to impact on the findings. We will explore the
impact of the level of bias by undertaking sensitivity analyses.
Measures of treatment e9ect
For dichotomous outcomes, e.g. death, cardiovascular events etc.
results will be expressed as risk ratio (RR) with 95% confidence
intervals (CI). Where continuous scales of measurement are used
to assess the eGects of treatment (e.g. creatinine clearance (CrCl),
GFR, SCr, proteinuria), the mean diGerence (MD) and its 95% CI will
be used, or the standardised mean diGerence (SMD) and its 95% CI
if diGerent scales have been used.
Unit of analysis issues
Data in diGerent metrics will be analysed by converting reported
values to SI units. The final results will be presented in International
System (SI) units with conventional units in parentheses.
Dealing with missing data
If possible, data for each outcome of interest will be evaluated,
regardless of whether the analysis is based on intention-to-treat
(ITT) or how complete the data are. In particular, drop-out rates
will be investigated and reported in detail such as drop-out due to
discontinuation of study drug, treatment failure, death, withdrawal
of consent or loss to follow-up. Missing data will be imputed when
possible and details will be reported.
Assessment of heterogeneity
We will test for heterogeneity with Cochran’s Q, which follows
a Chi2 distribution with n-1 degrees of freedom, and an
alpha of < 0.10 used for statistical significance. The extent of
heterogeneity will be assessed with I2, which ranges between
0% and 100% and expresses the proportion of between group
variability that is attributable to heterogeneity rather than chance
(Higgins 2003). I2 values above 75% are typically held to signify
extreme heterogeneity, whereas 25% and 50% correspond to
low and medium levels of heterogeneity, respectively. However,
considerable clinical heterogeneity is expected, therefore random
eGects models will be used for analysing the data.
Assessment of reporting biases
We will test for asymmetries in the inverted funnel plots (i.e. for
systematic diGerences in the eGect sizes between more precise and
less precise studies) using the original (Egger 1997) and modified
Egger tests (Harbord 2006) and the Begg and Mazumdar correlation
test (Begg 1994). There are many potential explanations for why
an inverted funnel plot may be asymmetric, including chance,
heterogeneity, publication and reporting bias (Terrin 2005). We
will refrain from judging funnel plot asymmetries based on visual
inspection as this has been shown to be misleading in empirical
research (Lau 2006). Publication bias will also be evaluated by
testing the robustness of the results according to publication,
namely, publication as full manuscript in a peer reviewed journal
versus studies published as abstracts/text/letters/editorials and
publication.
Data synthesis
Data will be pooled using the random eGects model. The fixed
eGects model will also be analysed to ensure robustness of the
model chosen and susceptibility to outliers. Methodological quality
of the selected studies will be reviewed by two independent
authors using the Cochrane Renal Group checklist.
 The GRADE approach developed by Grades of Recommendation,
Assessment, Development and Evaluation Working Group (GRADE
Working Group) will be used for evaluating the quality of evidence
for outcomes to be reported. Based on the GRADE approach, the
quality of a body of evidence, in terms of the extent to which one
can be confident that an estimate of eGect or association is close
to the quantity of specific interest, will be defined. Quality of a
body of evidence involves consideration of within-study risk of bias
(methodological quality), directness of evidence, heterogeneity,
precision of eGect estimates and risk of publication bias (Table 1).
Four levels of quality (Table 2) will be assigned to the evidence.
Subgroup analysis and investigation of heterogeneity
Heterogeneity will be investigated by analysing the data using
subgroups according to the following parameters:
• Population characteristics* Stage of CKD (pre-dialysis/conservative treatment, dialysis,
transplant, and KDOQI stages 1-5)* Presence or absence of co-morbidities (diabetes,
hypertension, dyslipidaemia, smoking, obesity, family
history of cardiovascular disease, baseline cardiovascular
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disease); percentage of patients with these co-morbidities in
each study* Age* Gender* Mean systolic blood pressure (below 140 mm Hg versus 140
mm Hg or above)* Ethnicity (White, Afro-American, Asian, other)* Presence or absence of previous cardiovascular events (e.g.
primary versus secondary prevention)* Time on dialysis (fewer than three years versus three years
or more) and modalities of dialysis (haemodialysis versus
peritoneal dialysis)* Time with a functioning transplant (fewer than three years
versus three years or more)• Intervention characteristics* Types, doses and route of administration of the antiplatelet
agents* Duration of intervention (less than 6 months, 6 to 12 months,
greater than 12 months)
If suGicient studies are available, we will conduct sensitivity
analysis based on allocation concealment, blinding of participants,
investigators and outcome assessors, attrition (above or below
10%), ITT analysis, and premature discontinuation of the study.
We will perform univariate meta-regression according to previously
described methods if suGicient studies are identified (Palmer 2007).
Sensitivity analysis
Sensitivity analyses will be undertaken to explore the robustness
of findings to key decisions in the review process. These will
be determined as the review process takes place (Higgins 2008).
Where direct comparisons studies between anti-platelet agents are
not available, we will attempt to perform indirect comparisons of
anti-platelet agent versus anti-platelet agent if suGicient data are
available (Song 2003). Sensitivity analysis will be undertaken to
explore the influence of the study methods quality on the results.
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A D D I T I O N A L   T A B L E S
 
Underlying methodology Quality rating
RCTs; or double-upgraded observational studies. High
Downgraded RCTs; or upgraded observational studies. Moderate
Double-downgraded RCTs; or observational studies. Low
Triple-downgraded RCTs; or downgraded observational studies; or case series/case Very low
Table 1.   Levels of quality of the body of evidence using the GRADE approach 
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1. Limitations in the design and implementation of available studies suggesting high likelihood of bias.
2. Indirectness of evidence (indirect population, intervention, control, outcomes).
3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses).
4. Imprecision of results (wide confidence intervals).
5. High probability of publication bias.
Table 2.   Factors that may decrease the quality level of a body of evidence 
 
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Phosphodiesterase Inhibitors explode all trees
2. MeSH descriptor Adenosine Diphosphate, this term only with qualifier: AI
3. MeSH descriptor Platelet Glycoprotein GPIIb-IIIa Complex, this term only with qualifier: AI
4. ((antiplatelet next agent*) or (anti-platelet next agent*)):ti,ab,kw
5. ((antiplatelet therap*) or (anti-platelet therap*)):ti,ab,kw
6. (platelet next aggregation next inhibit*):ti,ab,kw
7. (phosphodiesterase next inhibit*):ti,ab,kw
8. (thrombocyte next aggregation next inhibit*):ti,ab,kw
9. ((antithrombocytic next agent*) or (anti-thrombocytic next agent*)):ti,ab,kw
10.((antithrombocytic next therap*) or (anti-thrombocytic next therap*)):ti,ab,kw
11.alprostadil:ti,ab,kw
12.aspirin:ti,ab,kw
13.acetylsalicylic acid:ti,ab,kw
14.((adenosine next reuptake inhibit*) or (adenosine re-uptake inhibit*)):ti,ab,kw
15.(adenosine next diphosphate next receptor next inhibit*):ti,ab,kw
16.dipyridamole:ti,ab,kw
17.disintegrins:ti,ab,kw
18.epoprostenol:ti,ab,kw
19.iloprost:ti,ab,kw
20.ketanserin:ti,ab,kw
21.milrinone:ti,ab,kw
22.pentoxifylline:ti,ab,kw
23.(S-nitrosoglutathione):ti,ab,kw
24.S-nitrosothiols:ti,ab,kw
25.trapidil:ti,ab,kw
26.ticlopidine:ti,ab,kw
27.clopidogrel:ti,ab,kw
28.(sulfinpyrazone or sulphinpyrazone):ti,ab,kw
29.cilostazol:ti,ab,kw
30.(P2Y12 NEAR/2 antagonis*):ti,ab,kw
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31.prasugrel:ti,ab,kw
32.ticagrelor:ti,ab,kw
33.cangrelor:ti,ab,kw
34.elinogrel:ti,ab,kw
35."glycoprotein IIB/IIIA inhibitors":ti,ab,kw
36.abciximab:ti,ab,kw
37.eptifibatide:ti,ab,kw
38.tirofiban:ti,ab,kw
39.defibrotide:ti,ab,kw
40.picotamide:ti,ab,kw
41.beraprost:ti,ab,kw
42.ticlid:ti,ab,kw
43.aggrenox:ti,ab,kw
44.ditazole:ti,ab,kw
45.(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR
#40 OR #41 OR #42 OR #43 OR #44)
46.dialysis:ti,ab,kw
47.(hemodialysis or haemodialysis):ti,ab,kw
48.(hemofiltration or haemofiltration):ti,ab,kw
49.(hemodiafiltration or haemodiafiltration):ti,ab,kw
50.(PD or CAPD or CCPD or APD):ti,ab,kw
51.(renal next insufficiency):ti,ab,kw
52.(kidney next failure):ti,ab,kw
53.(kidney next disease*):ti,ab,kw
54.ur*emi*:ti,ab,kw
55.((chronic next kidney) or (chronic next renal)):ti,ab,kw
56.(CKF or CKD or CRF or CRD):ti,ab,kw
57.predialysis:ti,ab,kw
58.((end-stage next renal) or (end-stage next kidney) or (endstage next renal) or (endstage next kid-
ney)):ti,ab,kw
59.(ESKD or ESRD or ESKF or ESRF):ti,ab,kw
60.((kidney next transplant*) or (renal next transplant*) or (kidney next *graP*) or (renal next
*graP*)):ti,ab,tw
61.(#46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58
OR #59 OR #60)
62.(#45 AND #61)
MEDLINE 1. exp Platelet Aggregation Inhibitors/
2. exp Phosphodiesterase Inhibitors/
3. Adenosine Diphosphate/ai [Antagonists & Inhibitors]
4. Platelet Glycoprotein GPIIb-IIIa Complex/ai [Antagonists & Inhibitors]
5. Sulfinpyrazone/
6. (antiplatelet agents$ or anti-platelet agent$).tw.
7. (antiplatelet therap$ or anti-platelet therap$).tw.
8. platelet aggregation inhibit$.tw.
9. phosphodiesterase inhibit$.tw.
10.thrombocyte aggregation inhibit$.tw.
11.(antithrombocytic agent$ or anti-thrombocytic agent$).tw.
12.(antithrombocytic therap$ or anti-thrombocytic therap$).tw.
13.alprostadil.tw.
  (Continued)
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14.aspirin.tw.
15.acetylsalicylic acid.tw.
16.(adenosine reuptake inhibit$ or adenosine re-uptake inhibit$).tw.
17.adenosine diphosphate receptor inhibit$.tw.
18.dipyridamole.tw.
19.disintegrins.tw.
20.epoprostenol.tw.
21.iloprost.tw.
22.ketanserin.tw.
23.milrinone.tw.
24.pentoxifylline.tw.
25.S-nitrosoglutathione.tw.
26.S-nitrosothioles.tw.
27.trapidil.tw.
28.ticlopidine.tw.
29.clopidogrel.tw.
30.(sulfinpyrazone or sulphinpyrazone).tw.
31.cilostazol.tw.
32.(P2Y12 adj2 antagonis$).tw.
33.prasugrel.tw.
34.ticagrelor.tw.
35.cangrelor.tw.
36.elinogrel.tw.
37."glycoprotein IIB/IIIA inhibitors".tw.
38.abciximab.tw.
39.eptifibatide.tw.
40.tirofiban.tw.
41.defibrotide.tw.
42.picotamide.tw.
43.beraprost.tw.
44.ticlid.tw.
45.aggrenox.tw.
46.ditazole.tw.
47.or/1-46
48.exp Renal Dialysis/
49.(hemodialysis or haemodialysis).tw.
50.(hemofiltration or haemofiltration).tw.
51.(hemodiafiltration or haemodiafiltration).tw.
52.dialysis.tw.
53.(PD or CAPD or CCPD or APD).tw.
54.Renal Insufficiency/
55.Kidney Failure/
56.exp Renal Insufficiency, Chronic/
57.Kidney Diseases/
58.Uremia/
59.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
60.(ESRF or ESKF or ESRD or ESKD).tw.
61.(chronic kidney or chronic renal).tw.
62.(CKF or CKD or CRF or CRD).tw.
63.(predialysis or pre-dialysis).tw.
64.ur?emi$.tw.
  (Continued)
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65.or/48-64
66.and/47,65
EMBASE 1. exp Antithrombocytic Agent/
2. exp Phosphodiesterase Inhibitor/
3. Defibrotide/
4. platelet aggregation inhibit$.tw.
5. (antiplatelet agents$ or anti-platelet agent$).tw.
6. (antiplatelet therap$ or anti-platelet therap$).tw.
7. thrombocyte aggregation inhibit$.tw.
8. (antithrombocytic agent$ or anti-thrombocytic agent$).tw.
9. (antithrombocytic therap$ or anti-thrombocytic therap$).tw.
10.adenosine diphosphate receptor inhibit$.tw.
11.phophodiesterase inhibit$.tw.
12.(adenosine reuptake inhibit$ or adenosine re-uptake inhibit$).tw.
13.aspirin.tw.
14.acetylsalicylic acid.tw.
15.dipyridamole.tw.
16.ticlopidine.tw.
17.clopidogrel.tw.
18.(sulfinpyrazone or sulphinpyrazone).tw.
19.cilostazol.tw.
20.(P2Y12 adj2 antagonis$).tw.
21.prasugrel.tw.
22.ticagrelor.tw.
23.cangrelor.tw.
24.elinogrel.tw.
25."glycoprotein IIB/IIIA inhibit$".tw.
26.abciximab.tw.
27.eptifibatide.tw.
28.tirofiban.tw.
29.defibrotide.tw.
30.picotamide.tw.
31.beraprost.tw.
32.ticlid.tw.
33.aggrenox.tw.
34.ditazole.tw.
35.or/1-34
36.exp Renal Replacement Therapy/
37.(hemodialysis or haemodialysis).tw
38.(hemofiltration or haemofiltration).tw.
39.(hemodiafiltration or haemodiafiltration).tw.
40.dialysis.tw.
41.(PD or CAPD or CCPD or APD).tw.
42.Kidney Disease/
43.Chronic Kidney Disease/
44.Kidney Failure/
45.Chronic Kidney Failure/
46.Uremia/
47.(chronic kidney or chronic renal).tw.
48.(CKF or CKD or CRF or CRD).tw.
49.(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
  (Continued)
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50.(ESRF or ESKF or ESRD or ESKD).tw.
51.ur?emi$.tw.
52.exp Kidney Transplantation/
53.or/36-52
54.and/35,53
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Yes (low risk of bias): Random number table; computer random number generator; coin tossing;
shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be
implemented without a random element, and this is considered to be equivalent to being random).
No (high risk of bias): Sequence generated by odd or even date of birth; date (or day) of admission;
sequence generated by hospital or clinic record number; allocation by judgement of the clinician;
by preference of the participant; based on the results of a laboratory test or a series of tests; by
availability of the intervention.
Was there adequate se-
quence generation?
Unclear: Insufficient information about the sequence generation process to permit judgement.
Yes (low risk of bias): Randomisation method described that would not allow investigator/partici-
pant to know or influence intervention group before eligible participant entered in the study (e.g.
central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; se-
quentially numbered drug containers of identical appearance; sequentially numbered, opaque,
sealed envelopes).
No (high risk of bias): Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Was allocation adequately
concealed?
Unclear: Randomisation stated but no information on method used is available.
Yes (low risk of bias): No blinding, but the review authors judge that the outcome and the outcome
measurement are not likely to be influenced by lack of blinding; blinding of participants and key
study personnel ensured, and unlikely that the blinding could have been broken; either partici-
pants or some key study personnel were not blinded, but outcome assessment was blinded and
the non-blinding of others unlikely to introduce bias.
No (high risk of bias): No blinding or incomplete blinding, and the outcome or outcome measure-
ment is likely to be influenced by lack of blinding; blinding of key study participants and person-
nel attempted, but likely that the blinding could have been broken; either participants or some key
study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Was knowledge of the al-
located interventions ade-
quately prevented during
the study?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'
Were incomplete outcome
data adequately addressed?
Yes (low risk of bias): No missing outcome data; reasons for missing outcome data unlikely to be
related to true outcome (for survival data, censoring unlikely to be introducing bias); missing out-
come data balanced in numbers across intervention groups, with similar reasons for missing data
across groups; for dichotomous outcome data, the proportion of missing outcomes compared with
observed event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
 
Antiplatelet agents for chronic kidney disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
No (high risk of bias): Reason for missing outcome data likely to be related to true outcome, with
either imbalance in numbers or reasons for missing data across intervention groups; for dichoto-
mous outcome data, the proportion of missing outcomes compared with observed event risk
enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome
data, plausible effect size (difference in means or standardized difference in means) among miss-
ing outcomes enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis
done with substantial departure of the intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation.
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
Yes (low risk of bias): The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
No (high risk of bias): Not all of the study’s pre-specified primary outcomes have been reported; one
or more primary outcomes is reported using measurements, analysis methods or subsets of the da-
ta (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not
pre-specified (unless clear justification for their reporting is provided, such as an unexpected ad-
verse effect); one or more outcomes of interest in the review are reported incompletely so that they
cannot be entered in a meta-analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study.
Are reports of the study free
of suggestion of selective
outcome reporting?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
Yes (low risk of bias): The study appears to be free of other sources of bias.
No (high risk of bias): Had a potential source of bias related to the specific study design used;
stopped early due to some data-dependent process (including a formal-stopping rule); had ex-
treme baseline imbalance; has been claimed to have been fraudulent; had some other problem.
Was the study apparently
free of other problems that
could put it at a risk of bias?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
  (Continued)
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